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Abstract
Angiogenesis and cancer invasiveness greatly contribute to cancer malignancy. Arf6 and its effector, AMAP1, are
frequently overexpressed in breast cancer, and constitute a central pathway to induce the invasion and metastasis. In this
pathway, Arf6 is activated by EGFR via GEP100. Arf6 is highly expressed also in human umbilical vein endothelial cells
(HUVECs) and is implicated in angiogenesis. Here, we found that HUVECs also highly express AMAP1, and that vascular
endothelial growth factor receptor-2 (VEGFR2) recruits GEP100 to activate Arf6. AMAP1 functions by binding to cortactin in
cancer invasion and metastasis. We demonstrate that the same GEP100-Arf6-AMAP1-cortactin pathway is essential for
angiogenesis activities, including cell migration and tubular formation, as well as for the enhancement of cell permeability
and VE-cadherin endocytosis of VEGF-stimulated HUVECs. Components of this pathway are highly expressed in pathologic
angiogenesis, and blocking of this pathway effectively inhibits VEGF- or tumor-induced angiogenesis and choroidal
neovascularization. The GEP100-Arf6-AMAP1-cortactin pathway, activated by receptor tyrosine kinases, appears to be
common in angiogenesis and cancer invasion and metastasis, and provides their new therapeutic targets.
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Introduction
Vascular endothelial growth factors (VEGFs) are major factors
involved in angiogenesis [1–4]. A family member of VEGFs,
namely VEGF-A, was originally discovered as a vascular-
permeability factor [5]; and the primary function of VEGF
signaling involves enhancement of endothelial-cell permeability
and vascular leakage [6]. A small GTPase, Arf6, has been
implicated in VEGF signaling and angiogenesis. It has been shown
that expression of a dominant-negative form of Arf6, Arf6 (T27N),
in human umbilical vein endothelial cells (HUVECs) inhibits
vascular endothelial growth factor receptor-2 (VEGFR2)-mediated
intracellular signaling, such as Rac1 activation [7]. Consistently,
suppression of Arf6 activity via the Slit2-Robo4 pathway blocks
angiogenesis and promotes vascular stability [8]. However, the
mechanism as to how VEGFR2 regulates Arf6 activity, as well as
the mechanisms by which Arf6 functions in angiogenesis, and also
in other aspects of VEGF signaling, still largely remains elusive.
A small GTPase, Arf6, primarily regulates the recycling of
plasma membrane components and plays pleiotropic roles,
including membrane protrusion and remodeling [9,10]. We have
shown previously that different breast cancer cells overexpress
both Arf6 and its effector, AMAP1; and that overexpressed Arf6
and AMAP1 then constitute a robust signaling axis to induce
invasion and metastasis [11–15]. In invasion and metastasis,
GEP100, a guanine nucleotide exchanger for Arf GTPases, is
primarily responsible for Arf6 activation, and this activation
requires the association of GEP100 with ligand-activated epider-
mal growth factor receptor (EGFR) [15]. Pathological analyses
revealed that components of this pathway are highly expressed in
40–80% of primary tumors of the human breast [12,15]. AMAP1
functions by binding to cortactin in cancer invasion and
metastasis. Blocking of the GEP100-Arf6-AMAP1-cortactin path-
way by siRNAs or inhibitors effectively blocks breast cancer
invasion and metastasis [11–13,15]. Read-outs of this Arf6
pathway include the disruption of E-cadherin-based cell-cell
adhesions [15], by inducing E-cadherin endocytosis (our unpub-
lished results).
Protein expression of Arf6 is markedly augmented in HUVECs
when cultured with VEGF, and in a mouse hindlimb ischemia
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[7,16]. Here, we found that HUVECs also highly express AMAP1,
comparable to the levels observed in highly invasive breast cancer
cells. We also found that GEP100 physically associates with ligand-
activated VEGFR2 to activate Arf6, and that Arf6 then recruits
AMAP1. Like cancer invasion and metastasis, AMAP1 functions
by binding to cortactin in angiogenesis. This GEP100-Arf6-
AMAP1-cortactin pathway is essential not only for VEGF-induced
endothelial cell migration and tubular formation, but also for
VEGF-induced enhancement of VE-cadherin endocytosis and cell
permeability. Components of this pathway are highly expressed in
CD31-positive vessels with pathologic angiogenesis, and blocking
of this pathway effectively inhibits pathologic angiogenesis. Our
results reveal that the GEP100-Arf6-AMAP1-cortactin pathway,
activated by growth factor receptor tyrosine kinases, is common in
angiogenesis and invasion and metastasis of some breast cancer
cells, and hence provides new therapeutic targets for human
disorders characterized by hyper-angiogenesis and malignant
cancer development.
Materials and Methods
Cells
HUVECs were purchased from Iwaki and grown in endothelial
growth medium-2 (EGM2; Lonza), according to the manufactur-
er’s instruction. Note that EGM2 contains a low concentration of
VEGF, a concentration which is not open to public. MDA-MB-
231 and MCF7 cells, obtained from the American Type Culture
Collection, were cultured as described previously [15]. Cos-7 cells
were cultured in DMEM with 10% fetal calf serum (FCS,
Hyclone).
Angiogenesis
Quantification of angiogenic responses was performed by the
directed in vivo angiogenesis assay (DIVAA, Trevigen), according
to the manufacturer’s instructions. Briefly, 20 ml of VEGF
(500 ng ml
21) or MDA-MB-231 cells (5610
6 ml
21) was injected
into angioreactor tubes, which were filled with basement
membrane extracts; and tubes were then implanted subcutane-
ously into the dorsal areas of nude mice. Nine days later the tubes
were collected and the amounts of Isolectin B4 accumulated
within the basement membrane extracts were measured using a
multiplate fluorescent reader (ARVO, Perkin Elmer), after
proteolytic digestion of the basement membrane. For siRNA
treatment, RNA duplexes were mixed with AteloGene (Koken),
according to the manufacturer’s instructions; and 200 ml of the
mixture was injected into the bottom sides of angioreactor tubes
implanted in mice, at day 0 and day 4. P4-TAT peptide and the
control SC peptide were added into the angioreactor tubes before
implantation. These studies were performed at Osaka Bioscience
Institute, and the protocols used for animal experiments in this
study were approved by the Animal Research Committee of
Osaka Bioscience Institute (Permit number: 07-103).
Laser-induced CNV
CNV was conducted as described previously [17,18]. One day
before the laser administration, 5 mg kg
21 P4-TAT or SC peptide
was injected intraperitoneally into 2-month-old male C57BL/6
mice (CLEA Japan). The next day mice were anesthetized with
pentobarbital (0.05 mg g
21 body weight) and their pupils dilated
with 0.5% phenylephrine and 0.5% tropicamide (Santen). CNV
was induced with a 532 nm laser (Lumenis Novus Spectra). Four
laser spots (200 mW power, 75 mm spot size, 100 msec) were
placed in each eye using a slit-lamp delivery system and a cover
glass as a contact lens. Production of a bubble at the time of laser
treatment, indicating rupture of the Bruch’s membrane, is an
important factor in obtaining CNV; therefore, only burns in which
a bubble was produced were included in this study. Immediately
after laser treatment, 5 mg kg
21 P4-TAT or control scrambled
peptide was injected intraperitoneally every day for 7 days. On
experimental day 8, mice were anesthetized and perfused through
the left ventricle with 5 ml PBS followed by 2 ml of 0.5% FITC-
labeled dextran (Mr 2,000 kDa, Sigma) in 1% gelatin. The eyes
were enucleated and fixed in 2% paraformaldehyde for 30 min.
The anterior segment and retina were then removed from the
eyecup. About 4 to 6 relaxing radial incisions were made, and the
remaining retinal pigment epithelium (RPE)-choroidal-scleral
complex was flatmounted with Vectashield Mounting Medium
(Dako) and coverslipped. Flatmounts were examined with a
microscope (BIOREVO; Keyence) and images of each CNV were
digitally stored. Eyes with hemorrhagic complications such as
vitreous hemorrhage or subretinal hemorrhage caused by laser
irradiation were excluded from the evaluation. The average size of
the CNV lesions was then measured, and data are presented as the
mean 6 s.e.m. with n as indicated. The animal experiments were
conducted in accordance with the Association for Research in
Vision and Ophthalmology Statement for the Use of Animals in
Ophthalmic and Vision Research and the Committee for Animal
Use and Care of Hokkaido University.
VE-cadherin endocytosis
VE-cadherin endocytosis was assayed by the VE-cadherin
antibody-binding method, as described [19]. Briefly, HUVECs,
plated at a confluent density, were prestarved with EGM2 without
serum for 4 h, and then incubating with a monoclonal antibody
BV6(10 mg ml
21),whichisagainsttheextracellulardomainofVE-
cadherin, at4uC for1 h.Afterwashingoffthe unbound antibody by
rinsing cells with ice-cold EGM2, cells were then incubated at 37uC
for 30 min in the presence or absence of VEGF (50 ng ml
21). Cells
were then washed with 25 mM glycine (pH 2.5) containing 3%
bovine serum albumin for 15 min at an ambient temperature to
remove surface-bound antibodies, and fixed in 4% paraformalde-
hyde, permeabilized with 0.5% Triton X-100, and subjected to
labeling of internalized BV6 moleculesbyuseof an antibodyagainst
mouse IgG conjugated with Alexa Fluor 546 (Molecular Probes).
For siRNA treatment, cells were preincubated with RNA duplexes
for 48 h, before plating. For TAT peptide treatment, cells were
incubated with TAT peptides for 30 min at 37uC between the 4 h
starvation and the labeling with BV6. The number of cells
exhibiting at least one group of five or more acid-resistant VE-
cadherin-positive vesicle-like structures was counted (n.300).
Results are expressed as the mean 6 s.e.m. of three independent
experiments, and statical analysis was performed using ANOVA.
Other methods
GST-GGA pulldown, immunoprecipitation, immunoblotting,
antibodies and chemicals, cDNAs, siRNAs, transfections, tubular
formation, chemotactic transwell migration, two dimentional cell
migration activity immunohistochemical staining, cell permeabil-
ity, immunofluorescent microscopy, GST-PH binding, viability
and RT-PCR are described in the Supporting Materials and
Methods S1.
Results
VEGF activates Arf6 via GEP100 in endothelial cells
Although Arf6 activity is implicated in VEGF signaling and
angiogenesis, it is not yet shown whether VEGF activates Arf6. We
Arf6 Pathway Common to Angiogenesis and Invasion
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indeed induced activation of endogenous Arf6 (Figure 1A). This
activation was transient, peaked at 1 min and then declined, as
observed with other small GTPases [20]. HUVECs express
predominantly VEGFR2 among the VEGFR-family members.
Tyrosine phosphorylation of VEGFR2 occurred within 1 min,
peaked at 3 min and declined by 10 min after the stimulation
(Figure 1A).
Although signaling pathways downstream of VEGFR2 have
been extensively studied [21], none of them could interpret the
mechanisms of Arf6 activation. Moreover, more than a single type
of GEF can activate Arf6 [22,23]. We then sought to identify
GEF(s) primarily responsible for this VEGF-induced Arf6
activation. GEP100 binds to tyrosine phosphorylated EGFR
[15]. We tested whether GEP100 also binds to tyrosine
phosphorylated VEGFR2, and found that VEGFR2 is coprecipi-
tated with GEP100 in HUVECs endogenously, when cells were
stimulated by VEGF (Figure 1B). We then knocked down GEP100
by the siRNA method in HUVECs, and found that this
knockdown largely abolished the VEGF-induced activation of
Arf6 (Figure 1C and Figure S4). These results suggest that
GEP100 is primarily responsible for the VEGF-induced activation
of Arf6 in HUVECs.
VEGF signaling is known to activate Erk and Akt [21].
Silencing of GEP100 does not affect the activation of Erk and Akt
in HUVECs (Figure 1D). These results, together with the results
described above, confirm the specificity of GEP100 in VEGF
signaling, and indicate that the VEGF signaling pathway that
activates Arf6 is independent of that activating Erk and Akt in
HUVECs. Moreover, activation of Erk and Akt both occur
10 min after the VEGF stimulation, which is much slower than the
activation of Arf6.
Mode of GEP100 binding to ligand-activated VEGFR2
We next investigated the precise mechanism by which ligand-
activated VEGFR2 employs GEP100. The PH domain of
GEP100 binds to certain phosphorylated tyrosines of EGFR
[15]. We first examined whether this PH domain also binds to
Figure 1. GEP100 associates with ligand-activated VEGFR2 to activate Arf6. A, Activation of Arf6 and tyrosine phosphorylation of VEGFR2
upon VEGF stimulation of HUVECs. B, Coprecipitation of GEP100 with VEGFR2 upon VEGF stimulation of HUVECs, analysed by anti-GEP100
immunoprecipitation (IP) and anti-VEGFR2 immunoblot. PI, pre-immune serum. C–D, Activities of Arf6 (C), and Erk and Akt (D) in HUVECs transfected
with siRNAs for GEP100 or irrelevant sequences (Irr) upon VEGF stimulation. E, Coprecipitation of VEGFR2-V5 and its tyrosine phosphorylation-
deficient mutants (951F, 1175F and 1214F) with HA-GEP100 expressed in Cos-7 cells, analysed by anti-HA (GEP100) immunoprecipitation and anti-V5
(VEGFR2) immunoblot. F, Activation of Arf6-HA by VEGFR2-V5 or its mutants (951F, 1175F and 1214F) upon VEGF stimulation in Cos-7 cells, in which
non-tagged GEP100 cDNA was simultaneously transfected. In A–F,1 0n gm l
21 VEGF was used for stimulation for 1 min (+) or for the indicated times,
while controls included cells without stimulation (0 min or 2). Arf6 activities were assessed by the GST-GGA pulldown method (A, C, F). Total, total
cell lysates (20 mg). In A–D, HUVECs were cultured in low serum (0.5% FCS) medium for 16 h before stimulation. These assays were performed at least
twice and representative figures are shown.
doi:10.1371/journal.pone.0023359.g001
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tagged VEGFR2 in Cos-7 cells, and their lysates were pulled-down
in vitro with the PH domain of GEP100, fused to glutathione-s-
transferase (GST). We found that the GST-GEP100 PH domain
pulls down ligand-activated VEGFR2-V5, while PH domains of
ARNO or phospholipase Cd do not (Figure S1). VEGFR2 has 6
major tyrosines, phosphorylated upon VEGF stimulation: Tyr951,
Tyr996, Tyr1054, Tyr1059, Tyr1175 and Tyr1214 [21] (see
Figure S2). We synthesized these tyrosine peptides in their
phosphorylated form, and found that the GST-GEP100 PH
domain binds to the phosphorylated Tyr951 peptide, but not to
the other phosphorylated peptides (Figure S3). Furthermore, the
GST-GEP100 PH domain did not bind to the non-phosphorylated
Tyr951 peptide (Figure S3). We confirmed phosphorylation of
Tyr951 upon VEGF stimulation in HUVECs (Figure S5).
Based on these results, we then generated a mutant form of
VEGFR2-V5, in which Tyr951 was changed to phenylalanine
(951F) and expressed it in Cos-7 cells together with hemagglutinin
(HA)-tagged GEP100, and found that this mutant is not
coprecipitated with HA-GEP100 (Figure 1E). As a control, we
confirmed that wild type VEGFR2-V5 is coprecipitated with HA-
GEP100 (Figure 1E). Moreover, mutations of the other tyrosines,
such as Tyr1175 and Tyr1214, into phenylalanine (1175F and
1214F, respectively) did not affect the coprecipitation (Figure 1E).
We then expressed VEGFR2-V5 or its mutants together with
Arf6-HA and GEP100 in Cos7 cells, and measured activities of
Arf6-HA by use of the GST-GGA pulldown method [24]. We
found that the 951F mutant of VEGFR2-V5 does not induce the
activation of Arf6-HA in response to VEGF, while the 1175F and
1214F mutants, as well as wild type VEGFR2-V5, induce Arf6-
HA activation (Figure 1F). These results indicate that VEGFR2
physically associates with GEP100 to activate Arf6 upon VEGF
stimulation: an association which requires the binding of
phosphorylated Tyr951 of VEGFR2 and the PH domain of
GEP100. We also confirmed that the Tyr951-phosphorylated
form of VEGFR2 is coprecipitated with GEP100 from HUVECs
endogenously, upon VEGF stimulation (Figure S2).
Requirement for Arf6 in VEGF-induced tubular formation
and migration
Tubular (or capillary-like) network formation of HUVECs
cultured in vitro is one of the hallmark processes necessary for
angiogenesis [1,2]. To examine the involvement of Arf6 in VEGF-
induced angiogenesis, we then tested the effects of Arf6 siRNA.
Knockdown of Arf6 significantly impaired VEGF-induced tubular
formation, as compared to control irrelevant RNA duplexes (Irr)
(Figure 2A and Figure S4), without affecting cell viability
(Figure 2B). VEGF-induced cell migratory activity is another
hallmark of angiogenic activity [25]. Arf6 siRNA treatment
abolished VEGF-induced trans-migration activities almost com-
pletely, which were assessed using modified Boyden chambers [26]
(see Figure 2C). VEGF-induced two-dimensional migration
activities, assessed by the wound healing assay [27], was also
almost completely blocked by Arf6 siRNA treatment (Figure 2D).
High levels of AMAP1 expression in HUVECs and
involvement of GEP100 and AMAP1 in VEGF-induced
angiogenic activities
AMAP1 is a downstream effector for Arf6, and functions in
cancer invasion and metastasis [12]. Most malignant breast cancer
cells with high invasive activities abnormally overexpress both Arf6
and AMAP1 proteins, while weakly- or non-invasive breast cancer
cells express only marginal levels of these two proteins [11,12].
HUVECs are known to express Arf6 at a high level [7], which we
found to be almost equivalent to that observed with highly invasive
MDA-MB-231 breast cancer cells (Figure 3A). HUVECs also
express AMAP1 at a very high level, which is also comparable to
MDA-MB-231 cells (Figure 3A).
We next examined whether GEP100 and AMAP1 are involved
in VEGF-induced angiogenic activities in vitro. Knockdown of
GEP100 and AMAP1 each significantly affected VEGF-induced
tubular formation, and almost completely blocked VEGF-induced
cell migratory activities (Figure 3B–3D and Figure S4), without
affecting cell viability (Figure 3E). As a control, we also knocked
down AMAP2 [28] (see Figure S4), a close isoform of AMAP1,
and did not observe an inhibitory effect on tubular formation
(Figure 3B).
Requirement for cortactin and its association with
AMAP1 in VEGF-induced angiogenic activities
AMAP1 functions by forming a complex with cortactin in
invasive breast cancer cells [12,13]. We found that AMAP1 forms
a complex with cortactin also in HUVECs, and this complex
formation significantly increased when cells were cultured with
VEGF (Figure 4A). Moreover, cortactin siRNAs effectively
inhibited VEGF-induced angiogenic activities in vitro, without
affecting cell viability (Figure 3B and 3E).
We previously designed a cell-permeable peptide, namely P4-
TAT, that blocks AMAP1 and cortactin binding, and hence
inhibits cancer invasion and metastasis [13]. P4-TAT, but not the
control scrambled TAT-peptide (SC), blocked VEGF-induced
angiogenic activities in vitro, like tubular formation and cell
migration, in a dose-dependent manner, without affecting cell
viability (Figure 4B–4E). We confirmed that P4-TAT, but not SC,
blocks endogenous binding of AMAP1 with cortactin in HUVECs
(Figure 4F). These results indicate that AMAP1 functions via its
complex formation with cortactin in HUVECs, and this complex
formation is necessary for the VEGF-induced angiogenic activities.
Involvement of the Arf6 signaling pathway in
angiogenesis
We then examined whether the GEP100-Arf6-AMAP1-cortac-
tin pathway is involved in pathologic angiogenesis in vivo. For this,
we first confirmed that CD31-positive pathologic vessels [16] are
strongly positive for GEP100 and AMAP1 (Figure 5A). Antibodies
against Arf6 applicable to immunohistochemistry were not
available. We then tested GEP100 siRNAs and P4-TAT. For
this, angioreactor tubes [29], loaded with VEGF or MDA-MB-231
cells, were implanted into nude mice, and 9 days later the amounts
of Isolectin B4 accumulated within the tubes were measured.
MDA-MB-231 cells are known to produce several angiogenic
factors [30]. Administration of GEP100 siRNAs, pre-mixed with
AteloGene [31], into mice implanted with these angioreactors
inhibited their angiogenesis in a dose-dependent manner, while an
irrelevant RNA duplex did not (Figure 5B and 5D). P4-TAT, but
not SC, also inhibited this angiogenesis in a dose-dependent
manner (Figure 5C and 5E).
We moreover examined the effects of P4-TAT on choroidal
neovascularization (CNV), which is the main cause of severe vision
lossin patients with age-related macular degeneration [32], by the use
of laser-induced choroidal neovascularization in mice [17,18]. P4-
TAT or SC peptide was injected intra-peritoneally into mice daily
from a day before the laser treatment until the end of the experiment.
We chose intra-peritoneal administration rather than direct injection
into the eyes, to prevent injuring the eyes by the latter method. P4-
TAT was also effective in inhibiting CNV (Figure 5F and 5G).
Arf6 Pathway Common to Angiogenesis and Invasion
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permeability and VE-cadherin endocytosis
The primary function of VEGF signaling involves promoting
endothelial cell permeability and vascular leakage. VEGF
signaling induces endocytosis of VE-cadherin, and this endocytosis
is crucial for the enhancement of endothelial permeability [33,34].
We then investigated whether the GEP100-Arf6-AMAP1-
cortactin pathway is also involved in endothelial permeability and
VE-cadherin endocytosis. VEGF enhances the permeability of
intactHUVECsbytwofold,measuredbyparacellularmovementof
dextran molecules [19,35] (also see Figure 6A). We then examined
the effects of siRNAs for GEP100, Arf6 and AMAP1 on the
permeability. For siRNAs to be effective in this assay, siRNA
treatment must be started 36 h before the cells are re-plated onto
chambers to form confluent monolayers. We found that HUVECs,
treatedwith thesesiRNAsalreadyexhibit high levels ofpermeability
even without VEGF, and do not respond to VEGF stimulation to
change their permeability, (Figure 6A). We next measured the rates
of endocytosis of VE-cadherin, from the plasma membrane into the
cytoplasm. VEGF accelerates VE-cadherin endocytosis by several
folds in intact HUVECs [19] (see Figure 6B and 6C). As in the case
of permeability, HUVECs treated with GEP100, Arf6 or AMAP1
siRNAs, all exhibited high rates of the VE-cadherin uptake even
without VEGF, and did not respond to VEGF (Figure 6B and 6C).
Intact HUVECs exhibit VE-cadherin-based cell-cell junctions with
high integrity, while VEGF stimulation evokes their irregular,
disorganized morphology [19] (also see Figure 6B). We found that
VE-cadherin-based cell-cell junctions become disorganized even
without VEGF stimulation, when cells are treated with these
siRNAs (Figure 6B). In these experiments, irrelevant and AMAP2
siRNAs were used as negative controls. These results suggest that
loss of these proteins disturbs cells to form their intact cell-cell
adhesions, and cells with such disorganized cell-cell adhesions are
no longer sensitive to VEGF regulation.
We then tested P4-TAT. Unlike the siRNA-treatments
described above, P4-TAT can be added directly to cell cultures
that are confluent and already form normal, intact cell-cell
adhesions. We found that addition of 10 mM P4-TAT to the
confluent culture blocks the VEGF-mediated enhancement of the
cell permeability, while it does not affect the permeability in the
absence of VEGF (Figure 6D). Likewise, P4-TAT blocked VEGF-
induced endocytosis of VE-cadherin, while it did not cause
internalization of VE-cadherin in cells cultured in the absence of
VEGF (Figure 6E and 6F). VEGF-induced morphological changes
of the cell-cell junctions were also blocked by P4-TAT (Figure 6E).
These effects of P4-TAT were dose-dependent, and the control SC
peptide did not exhibit such inhibitory effects (Figure 6D–6F).
Taken together, we conclude that the GEP100-Arf6-AMAP1-
cortactin pathway is essential for the VEGF regulation of
endothelial cell permeability and VE-cadherin endocytosis. Our
results also suggest that components of this pathway may
essentially be involved in the formation of intact endothelial cell-
cell adhesions, as the cell culture medium already contains a low
concentration of VEGF.
Figure 2. Arf6 is necessary for VEGF-induced angiogenic activities. HUVECs, treated with siRNAs for Arf6 or irrelevant sequences (Irr), were
subjected to the tubular network formation assay in the presence of 10 ng ml
21 VEGF (A), to a viability assay (B), and to a migration assay using a
modified Boyden chamber (C) or using a wound healing assay (D) in the presence and absence of VEGF (10 ng ml
21). In A and D, assays were
performed more than two times, and representative figures are shown. In B, more than 1610
4 cells were scored in each assay. In C, data are
presented as the number of cells observed per microscopic field (620) which transmigrated the Boyden chamber filter. Six fields were counted in
each assay. Error bars show mean 6 s.e.m., n=3. * p,0.05.
doi:10.1371/journal.pone.0023359.g002
Arf6 Pathway Common to Angiogenesis and Invasion
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23359Discussion
Angiogenesis and cancer invasion share several common
properties [36]. We have shown previously that the GEP100-
Arf6-AMAP1-cortactin pathway is used for invasion and metas-
tasis of many breast cancer cells; and in this paper, we show that
this pathway is also used in angiogenesis, including breast cancer-
induced angiogenesis and choroidal neovascularization. Overex-
pression of Arf6 and AMAP1 proteins is necessary for the efficient
functioning of this pathway in invasion and metastasis [11,12].
Both Arf6 and AMAP1 are also expressed at high levels in
endothelial cells, as seen with highly invasive breast cancer cells.
Moreover, this pathway is activated by VEGFR2 in endothelial
cells and by EGFR in breast cancer cells [15], both of which are
receptor tyrosine kinases.
The GEP100-Arf6-AMAP1-cortactin pathway may at least be
involved in the sprouting process of angiogenesis, because
remodeling of the VE-cadherin-based cell-cell junctions as well
as cell migration/tubular network formation activities are all
required in this process. On the other hand, controlling
endothelial permeability should not necessarily accompany the
sprouting of new tubules, as well as cell migration. We do not
know whether the GEP100-Arf6-AMAP1-cortactin pathway can
simply regulate endothelial permeability, or VE-cadherin endocy-
tosis, without inducing cell migration or tubular network
formation activities (also see below).
VEGF signaling is linked to the activation of Src tyrosine kinases
[37,38]. Our results indicate that VEGFR2 utilizes phospho-
Tyr951 to bind to GEP100. Interestingly, VEGFR2 also utilizes
phospho-Tyr951 to activate Src kinases, which is mediated by the
binding of VRAP to phospho-Tyr951 [39]. VEGFR2-activated
Src may then activate the Vav2-Rac-PAK pathway, in which PAK
is proposed to phosphorylate VE-cadherin and recruit b-arrestin 2
to induce endocytosis of the phosphorylated VE-cadherin [19].
This pathway was described to be linked to vascular permeability.
However, engagement of VRAP, and the activation of Src as well,
has also been shown to activate endothelial cell migration [39].
Therefore, like mentioned above, it still remains to be elucidated
as to how VEGFR2 signaling pathways, employing Src kinases,
can be controlled in order to simply enhance vascular permeabil-
ity. It also remains to be investigated as to how VEGFR2 chooses
to act via GEP100 or VRAP, or both.
It has been reported that ARNO is also responsible for
activating Arf GTPases in VEGF signaling [8,24]. Among the
ArfGEFs, HUVECs express GEP100, Cytohesin1, ARNO, BIG2,
GBF1 and KIAA0522 at high levels, and Cytohesin3, Cytohesin4,
EFA6C and EFA6D at low levels (Figure S6). Several of these,
including GEP100 and ARNO, can activate Arf6 [23]. On the
other hand, ARNO can also activate Arf1 [23], while GEP100
exhibits a high specificity for Arf6 [40]. It is likely that VEGFR2
signaling employs different ArfGEFs, in addition to GEP100, to
activate different Arf GTPases, while the precise mechanisms
involved in activating ArfGEFs other than GEP100 largely remain
to be clarified.
Several angiogenic inhibitors are already in clinical use,
including those targeting VEGFs and VEGFR2 [41,42]. However,
inhibition of all VEGF signaling pathways often exhibits side
effects of cardiotoxicity, such as haemorrhage and hypertension
[43]. We show that silencing GEP100 does not block other
signaling pathways of VEGFR2, such as activating Erk and Akt.
Silencing of Arf6, GEP100, and AMAP1 neither affected cell
viability. Moreover, tumors that are initially sensitive to VEGF
blockage may often develop resistance [42,44,45], and hence
identification of additional targets is necessary [46]. On the other
Figure 3. Arf6 signaling components, GEP100, AMAP1 and cortactin, are all necessary for VEGF-induced angiogenic activities.
A, Expression of Arf6 and AMAP1 proteins in HUVECs and its comparison with those in invasive (MDA-MB-231) and non-invasive (MCF7) breast cancer
cells, by immunoblotting 20 mg of total cell lysates using antibodies as indicated. b-actin was used as a control. B–E, HUVECs, treated with siRNAs for
GEP100, AMAP1, cortactin or irrelevant sequences (Irr), were subjected to the tubular formation assay (B), modified Boyden chamber assay
(C), wound healing assay (D) or cell viability assay (E), as in Figure 2. AMAP2 siRNAs were included as another control (B, E). These assays were
performed at least two times, and representative figures are shown. Error bars show mean 6 s.e.m., n=3. * p,0.05.
doi:10.1371/journal.pone.0023359.g003
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disrupting preexisting vascular vessels may have a limitation in
killing the tumor cells located at the peripheral rim of tumors [47].
Since the GEP100-Arf6-AMAP1 pathway is common in patho-
logic angiogenesis and invasion/metastasis of many breast cancers,
we propose that components of the GEP100-Arf6-AMAP1-
cortactin pathway provide novel molecular targets for treatment
of malignant cancers, as well as other diseases characterized by
hyper-angiogenesis. Moreover, in both angiogenesis and cancer
invasion/metastasis, AMAP1 functions by forming a complex with
cortactin. The interface structure of this binding is very unusual
[13], and would also be an excellent novel target to inhibit these
malignant diseases. Lastly, it is also interesting to examine whether
the GEP100-Arf6-AMAP1 pathway is essential also for the cancer
neo-vascularization [48], since this pathway may be integral for
the generation of cancer stem-like cells [49].
Figure 4. P4-TAT blocks VEGF-induced angiogenic activities. A, Coprecipitation of cortactin with AMAP1 in HUVECs cultured in the presence
of 10 ng ml
21 VEGF, analysed by anti-AMAP1 immunoprecipitation and anti-cortactin immunoblot, as indicated. PI, pre-immune serum.
B–D, HUVECs, cultured in the presence of P4-TAT (P4) or a scrambled cell permeable peptide (SC) at 10 mM( C, D, F) or at concentrations as indicated
(B, E) for 1 h prior to analysis, were subjected to the tubular formation assay (B), modified Boyden chamber assay (C), wound healing assay (D) and
cell viability assay (E), as in Figure 2, in the presence of the peptides. Coprecipitation of cortactin with AMAP1 in these cells was analysed as above
(F). Total, total cell lysates (20 mg). These assays were performed at least two times, and representative figures are shown. Error bars show mean 6
s.e.m., n=3. * p,0.05.
doi:10.1371/journal.pone.0023359.g004
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23359Figure 5. Blockage of pathologic angiogenesis by GEP100 siRNA and P4-TAT. A, Immunohistochemistry of granulation tissue and scar
tissue sections by use of the indicated antibodies. Bars, 100 mm. B–E, Effects of GEP100 siRNAs and P4-TAT (P4) on angiogenesis were measured using
angioreactors implanted into nude mice, that contained basement membrane extracts and VEGF (500 ng ml
21) or MDA-MB-231 cells (1610
5 cells);
and amounts of Isolectin B4 accumulated within the basement membrane extracts were measured after incubation for 9 days. siRNAs, mixed with
AteloGene at concentrations as indicated, were injected into mice at day 0 and day 4. TAT-peptides were added into angioreactors before
implantation, at the indicated concentrations. An irrelevant RNA duplex (Irr) or a scrambled peptide (SC) was used as controls. Error bars show mean
6 s.e.m., n=8. * p,0.05. F–G, Effect of P4-TAT on CNV formation. Representative micrographs of CNV lesions in choroidal flatmounts from an animal
treated with P4-TAT or SC. Red dashed line shows the extent of the CNV lesions filled with FITC-dextran. Scale bar, 100 mm. Quantitative analysis of
the average CNV size is shown in G. Error bars show mean 6 s.e.m., n=70 to 77. *P,0.05.
doi:10.1371/journal.pone.0023359.g005
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e23359Figure 6. Requirement for the GEP100-Arf6-AMAP1-cortactin pathway in VEGF-induced cell permeability and VE-cadherin
endocytosis. HUVECs, treated with siRNAs for Arf6, GEP100, AMAP1 or an irrelevant sequence (Irr) (A–C), or by P4-TAT (P4) or SC peptide (D–F),
were subjected to a permeability assay by measuring paracellular movement of FITC-dextran (Mr 40 kDa) (A, D), and to a VE-cadherin uptake assay
by tracking endocytosis of cell surface VE-cadherin molecules (B, C, E, F). In A-C, cells were pretreated with siRNAs for 36 h before plating. In D–F,
TAT peptides were added to the confluent culture and incubated for 30 min prior to analysis. VE-cad, green; nuclei, blue. The scale bars represent
10 mm. Error bars show mean 6 s.e.m., n=3. *P,0.05.
doi:10.1371/journal.pone.0023359.g006
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Figure S1 PH domain from GEP100 associates with
ligand-activated VEGFR2. In vitro coprecipitation of
VEGFR2-V5 with the GST-fused PH domain of GEP100,
ARNO or phospholipase Cd (PLCd), expressed in Cos-7 cells and
analysed by glutathione-beads pulldown and anti-V5 immuno-
blot. VEGF (10 ng ml
21) treatment was for 1 min. Total, total
cell lysates (20 mg). GST-fusion proteins were visualized by
Ponceau S.
(TIF)
Figure S2 Tyr951-phosphorylated VEGFR2 was co-im-
munoprecipitated with GEP100 upon VEGF stimulation.
Phosphorylation of Tyr951 (pY951), Tyr996 (pY996), Tyr1054/
1059 (pY1054/1059), Tyr1175 (pY1175), and Tyr1214 (pY1214)
of VEGFR2 and its coprecipitation with GEP100 in HUVEC
cells, analysed using phosphotyrosine-specific antibodies and anti-
GEP100 immunoprecipitation. VEGF (10 ng ml
21) treatment was
for 1 min. Total, total cell lysates (20 mg).
(TIF)
Figure S3 Interaction of the PH domain of GEP100 with
the pY951 peptide in a dot-blot assay. Peptides were
spotted onto a nitrocellulose membrane (3, 1, and 0.3 mg
spot
21), and incubated with 5 mgm l
21 of GST-PH proteins
derived from GEP100 or GST after the membrane was blocked
with 5% bovine serum albumin. After washing, GST proteins
retained on the membrane were visualized using an anti-GST
antibody (left and middle panels). Coomassie brilliant blue
(CBB) staining of the membrane is also shown in the right panel.
These assays were performed at least two times and represen-
tative figures are shown.
(TIF)
Figure S4 siRNA-mediated knockdown of the expres-
sion of either Arf6, GEP100, AMAP1, cortactin or AMAP2
in HUVECs. Cells were transfected with siRNA duplexes
against each indicated molecule, or with irrelevant sequences
(Irr), and analysed for expression of the indicated proteins by
immunoblotting of cell lysates using the appropriate antibody, as
indicated.
(TIF)
Figure S5 Phosphorylation of Tyr951 (pY951) and
tyrosine (pY) of VEGFR2 upon VEGF stimulation of
HUVECs. HUVECs were cultured in low serum (0.5% FCS)
medium for 16 h before stimulation. 10 ng ml
21 VEGF was used
for stimulation for the indicated times, while controls included cells
without stimulation (0 min). Total, total cell lysates (20 mg).
(TIF)
Figure S6 Expression of ArfGEF mRNAs in HUVECs.
Expression of ArfGEF mRNAs was analysed by RT-PCR, coupled
with agarose gel electrophoresis. Two ng of cDNA corresponding
to each indicated ArfGEF was used as positive controls (PC). NC,
without template cDNAs.
(TIF)
Materials and Methods S1 GST-GGA pulldown, immuno-
precipitation, and immunoblotting.
(DOCX)
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